NCT07167433 Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
| NCT ID | NCT07167433 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Ovarian Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-09-19 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2025-09-19 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemotherapy, and referrals to geneticists for OC patients. By identifying the strengths and weaknesses of the existing care, this project intends to generate valuable insights that can lead to the implementation of quality parameters for the treatment of ovarian cancer in the country.
Eligibility Criteria
Inclusion Criteria: * Patients ≥18 years old; * Newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021; * Irrespective of histology Exclusion Criteria: * Borderline tumors; * Pregnancy; * Synchronous tumor or second primary in the last 5 years (except thyroid cancer and non-melanoma skin cancer);
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07167433 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07167433 currently recruiting?
Yes, NCT07167433 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07167433 trial being conducted?
This trial is being conducted at Barretos, Brazil, Belo Horizonte, Brazil, Belo Horizonte, Brazil, Brasília, Brazil and 9 additional locations.
Who is sponsoring the NCT07167433 clinical trial?
NCT07167433 is sponsored by AstraZeneca. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.